Cargando…
Low-dose augmentation with buprenorphine increases emotional reactivity but not reward activity in treatment resistant mid- and late-life depression
Buprenorphine is currently being studied for treatment-resistant depression because of its rapid effect, relative safety, and unique pharmacodynamics. To understand the neural impact of buprenorphine in depression, we examined acute limbic and reward circuit changes during an intervention with low-d...
Autores principales: | Lin, Chemin, Karim, Helmet T., Pecina, Marta, Aizenstein, Howard J., Lenze, Eric J., Blumberger, Daniel M., Mulsant, Benoit H., Kharasch, Evan D., Reynolds III, Charles F., Karp, Jordan F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356006/ https://www.ncbi.nlm.nih.gov/pubmed/30685701 http://dx.doi.org/10.1016/j.nicl.2019.101679 |
Ejemplares similares
-
Low-Dose Augmentation With Buprenorphine for Treatment-Resistant Depression: A Multisite Randomized Controlled Trial With Multimodal Assessment of Target Engagement
por: Lee, Hyewon H., et al.
Publicado: (2021) -
Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression
por: Karim, Helmet T., et al.
Publicado: (2018) -
Cortical inhibition, facilitation and plasticity in late-life depression: effects of venlafaxine pharmacotherapy
por: Lissemore, Jennifer I., et al.
Publicado: (2021) -
Association of Molecular Senescence Markers in Late-Life Depression With Clinical Characteristics and Treatment Outcome
por: Diniz, Breno S., et al.
Publicado: (2022) -
Recruiting for a randomized clinical trial for late-life depression during COVID-19: outcomes of provider referrals vs. Facebook self-referrals
por: Ainsworth, Nicholas, et al.
Publicado: (2023)